



# Helping your patients with ATTR amyloidosis get the most out of the Acapella Patient Support Programme



Your patients can scan the QR code here or follow this [link](#) to sign up to Acapella.



Scan the QR code here or follow this [link](#) to access more information on the WAINZUA®▼ (eplontersen) website about how Acapella can support your patients.

WAINZUA®▼ (eplontersen) is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy.<sup>1</sup>

Prescribing information for WAINZUA can be found on the last page of this document.

Acapella is a Patient Support Programme initiated, managed and fully funded by AstraZeneca UK. This leaflet is intended for healthcare professionals in the UK only.

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting <https://contactazmedical.astrazeneca.com/> or by calling 0800 783 0033.

1. WAINZUA® (eplontersen) Summary of Product Characteristics.

# Welcome to the Acapella Patient Support Programme

Here you can find out more information about how the Acapella Patient Support Programme can help support your patients with ATTR amyloidosis and who have been prescribed WAINZUA® (eplontersen). To support patients' use of Acapella after their appointment, there is also a patient-facing guide, which you can give them to take home.

## Acapella healthcare team

Along with the care you provide for your patients, the Acapella healthcare team can offer additional support to your patients with ATTR amyloidosis. Once your patient has signed up to Acapella, they will have access to specialist services with the Acapella healthcare team. This includes a team of:

An illustration showing four people interacting with various food items like broccoli, avocado, tomatoes, and eggs. One person is holding a large green leafy vegetable, another is holding an avocado, and others are near a bowl of food.

**Dietitians**

An illustration of two women sitting on a light blue sofa, talking. There are plants and a laptop on the sofa.

**Counsellors**

An illustration of a woman walking a large brown dog in a park-like setting with trees and grass.

**Physiotherapists**

An illustration of a male doctor in a white coat sitting at a desk with a laptop, talking to a female patient sitting across from him. There are some papers and a clock on the wall.

**Nurse Support**

There are a range of appointments your patients can book with the Acapella healthcare team to get support with different parts of their care, from managing gastrointestinal symptoms to coping with their emotions.

Your patients can book a phone or video appointment with the Acapella healthcare team. They can refer to their Acapella Patient Support Programme guide for more information on how to book an appointment.

# Exploring the website

The Acapella website includes a range of information about ATTR amyloidosis and support for treatment with WAINZUA. Each section has a few articles to provide further information and education to your patient. You can advise them to read through these articles by clicking the '**Read more >**' button. Find out more about what each section entails and how the platform can support your patients:



**About ATTR Amyloidosis** – your patients can learn about the symptoms and different types of ATTR amyloidosis, and how a person may be affected by living with the condition.



**What to expect** – this section provides an overview of the different management approaches for ATTR amyloidosis and how your patients can prepare for the various tests and scans.



**Life with amyloidosis** – designed to help patients optimise management of their ATTR amyloidosis, this section shares advice and tips about how to make lifestyle changes that can support with managing symptoms of ATTR amyloidosis and day-to-day life, from staying active to seeking support at work.



**Support for you** – to ensure your patient has access to the support they need, this section provides guidance on how to book a service with the Acapella healthcare team and encourages them to seek support from others, such as joining a patient group or learning about the role of a caregiver.



**About your treatment** – with a comprehensive overview of the information a patient needs to know about WAINZUA, this section details how to use the treatment and any potential side effects they may experience when on the treatment.

# Signing up and joining the Acapella Patient Support Programme

To ensure your patients can successfully enrol onto Acapella and access all available support services, please review the enrolment steps below so you can help guide them through the process.

For more guidance on how to register, you can refer your patients to their Acapella Patient Support Programme guide.

1. Your patients will need to complete a registration form.
  - First, they will need to select the following options from the two drop-down menus: **'Amyloidosis'** and **'Polyneuropathy ATTR'**
  - Then, they will need to fill in some personal details, such as their name, date of birth, email address and home address
2. A confirmation email will be sent to your patient's email address – remind them to check their junk or spam folder if the email does not arrive.
3. Once they receive the confirmation email, they will need to click on **'Verify your email'** to complete their registration.
4. Next, they should be taken to a new webpage where they can create a password to login. You may want to help them think of a secure password that they will remember.
  - Remind your patient that their password should contain letters, numbers, special characters and should be at least 8 characters long.  
Allowed special characters include: ! " # \$ % & ' ( ) \* + , - . / : ; < = > ? @ [ \ ] ^ \_ ` { | } ~
5. Once they have created a password, they will be taken to a new webpage. To join the programme, they will need to provide:
  - Information about the care programme – your patients should select the following options:
    - Care programme – **Amyloidosis**
    - Brands – **WAINZUA**
    - Indication – **Polyneuropathy ATTR**
  - Consent to join the Acapella Patient Support Programme
  - Preferred contact methods

# PRESCRIBING INFORMATION

## WAINZUA® ▼ (eplontersen) 45MG SOLUTION FOR INJECTION IN PRE-FILLED PEN

Consult Summary of Product Characteristics (SmPC) before prescribing. **Indication:**

For the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy.

**Presentation:** Pre-filled pen containing 45mg eplontersen in 0.8mL.

**Dosage and Administration:** Treatment should be prescribed and supervised by physicians experienced in the diagnosis and treatment of amyloidosis. The recommended dose is 45mg of eplontersen by subcutaneous injection administered monthly. If a dose is missed, the dose should be administered as soon as possible. Thereafter, the patient can resume dosing at monthly intervals from date of last dose. A patient or their caregiver may administer Wainzua after being trained in subcutaneous injection technique. The pre-filled pen should be removed from refrigerated storage at least 30 minutes before use and allowed to reach room temperature prior to injection. Self-administer as a subcutaneous injection into the upper thigh or abdomen. If a healthcare professional or caregiver administers the injection, the upper arm can also be used. A patient should not self-inject in the arm. It should not be injected into skin which is tender, bruised, erythematous, or hard, into scars or damaged skin or area around the navel area.

**Elderly population:** No dosing adjustment is required for patients  $\geq 65$  years of age. **Renal impairment:** No dose adjustment is necessary in patients with mild to moderate renal impairment (estimated glomerular filtration rate [eGFR]  $\geq 45$  to  $< 90$  mL/min/1.73 m<sup>2</sup>). Eplontersen has not been studied in patients with eGFR  $< 45$  mL/min/1.73 m<sup>2</sup> or end-stage renal disease and should only be used in these patients if clinical benefit outweighs the potential risk.

**Hepatic impairment:** No dosing adjustment is necessary in patient with mild hepatic impairment. Wainzua has not been studied in patients with moderate to severe hepatic impairment, the clinical benefit must outweigh the potential risk if used in these patients. **Patients undergoing liver transplant:** The safety and efficacy of Wainzua in patients undergoing liver transplant has not been established.

**Paediatric population:** The safety and efficacy of Wainzua in children and adolescents under 18 years of age has not been established. **Contraindications:** Hypersensitivity to the active substance or excipients. **Warnings and Precautions:**

**Vitamin A deficiency:** Wainzua is expected to reduce serum vitamin A, and any symptoms or signs related to vitamin A deficiency should be evaluated prior to initiation of treatment. Patients receiving Wainzua should take oral supplementation of approximately, but not exceeding, 2 500 IU (female) to 3 000 IU (male) of vitamin A per day to reduce the potential risk of ocular symptoms due to

vitamin A deficiency. Vitamin A levels below the lower limit of normal should be corrected. Before initiating treatment with Wainzua exclude pregnancy and advise patients on effective contraception. Discontinue Wainzua and vitamin A supplementation if a women intends to become pregnant, or in the event of an unplanned pregnancy. Due to the long half-life of eplontersen a Vitamin A deficiency may develop after cessation of treatment. No recommendation can be given whether to continue or discontinue vitamin A supplementation during the first trimester of an unplanned pregnancy. **Sodium Content:** Wainzua is considered essentially 'sodium-free'. **Drug Interactions:** Wainzua is not expected to cause or be affected by drug-drug interactions. **Pregnancy and Lactation:** Wainzua should not be used during pregnancy. Wainzua should not be initiated in pregnant women or women intending to become pregnant. There is no data for the use of Wainzua in pregnant women. Wainzua will reduce the plasma levels of vitamin A, which is crucial for normal foetal development. It is not known whether vitamin A supplementation will be sufficient to reduce the risk to the foetus. **Lactation:** A risk to the breastfed child cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from Wainzua therapy, taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. **Ability to Drive and Use Machines:** Wainzua has no or negligible influence on the ability to drive and use machines. **Undesirable Events:** Consult SmPC for full list of side effects. **Very Common ( $\geq 1/10$ ):** Vitamin A decreased. **Common ( $\geq 1/100$  to  $< 1/10$ ):** Vomiting, proteinuria, cataracts, injection site reactions (erythema, pain, pruritus).

**Legal Category:** POM. **Marketing Authorisation Number:**

Wainzua 45mg solution for injection in pre-filled pen PLGB 17901/0377

**Presentation & Basic NHS Cost:** Wainzua 45mg solution for injection in pre-filled syringe 1 x single use pre-filled pen: £31,954.12

**Business Responsible for Sale and Supply / Further Information:** AstraZeneca UK Limited, 2

Pancras Square, 8<sup>th</sup> Floor, London, N1C 4AG, UK.

WAINZUA is a registered trademark of the AstraZeneca group of companies. Date of preparation 01/2025.

CV 24 0090a

Adverse events should be reported.

Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting

<https://contactazmedical.astrazeneca.com>

or by calling 0800 783 0033